Karyopharm posts ASCO 2026 SENTRY trial presentation on selinexor plus ruxolitinib in myelofibrosis

Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics, Inc.

KPTI

0.00
  • Karyopharm published Phase 3 SENTRY trial results for selinexor with ruxolitinib in JAK inhibitor-naive myelofibrosis.
  • Combination met the Week 24 SVR35 spleen volume endpoint versus ruxolitinib alone, with rapid, deep, sustained reductions across subgroups.
  • Symptom improvement at Week 24 was similar between treatment arms, with meaningful declines from baseline.
  • Overall survival signal reported, with greater spleen volume reduction linked to improved survival.
  • Manageable safety profile consistent with known profiles; higher variant allele frequency reductions observed as early as Week 24.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.